The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTI) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
Young Singaporean women are likely to get themselves immunized against human papillomavirus (HPV) with the motivation to protect their own health, positive information about the vaccine and parental encouragement, as reported in a recent qualitative study.
New drug applications approved by US FDA as of 16 - 31 August 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Influenza burden in Singapore has been on the rise since 2010, with young children (aged ≤4 years) and the elderly (aged ≥65 years) being most susceptible to influenza‐associated hospitalization for pneumonia and influenza (P&I), a local study has shown.
Infection with hepatitis B virus (HBV) does not appear to independently affect pregnancy outcomes, although it contributes to prolonged infertility, higher odds of secondary infertility, ovulatory disorders and reduced implantation rate, a study has found.
Dolutegravir demonstrated noninferiority to low-dose efavirenz in antiretroviral (ART)-naïve patients with HIV-1 infection in a resource-limited setting, according to the NAMSAL ANRS 12313* study presented at IAS 2019.
Vocinti® (vonoprazan), a first-in-class potassium-competitive acid blocker (P-CAB) is now available in Malaysia for use in Helicobacter pylori eradication therapy and erosive (reflux) oesophagitis treatment.
Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.
The addition of ezetimibe improves statin treatment in acute coronary syndrome (ACS) patients with dyslipidaemia and low eicosapentaenoic acid-to-arachidonic acid (EPA/AA) ratio, resulting in a lowered risk of cardiovascular events compared to monotherapy, according to a study presented at the recently concluded 2019 Congress of the European Society of Cardiology (ESC 2019) held in Paris, France.